2 Result: Argenx
Medical Breakthroughs: argenx's VYVGART Hytrulo and Pfizer's TALZENNA Garner FDA Approval
June 21st, 2023
argenx SE (Nasdaq: ARGX) has received approval from the U.S. Food and Drug Administration (FDA) for VYVGART Hytrulo, a subcutaneous injection used to treat generalized myasthenia gravis (gMG) in adult patients who test positive for anti-acetylcholine. Read more
Akebia Therapeutics, MDxHealth, Avis Budget, argenx, Five9, Inventiva: Analyst Upgrades and Initiations Point to Potential Upsides
May 31st, 2023
Akebia Therapeutics, Inc. (Nasdaq: AKBA), a biopharmaceutical company, received an upgrade from Neutral to Overweight by Piper Sandler, with the price target raised from $2 to $4. On Wednesday, $AKBA closed at $1.04, indicating a potential u. Read more
Want To Find Some News?
Recent Post
-
Honeywell, Intel, and Dover Earnings Preview: What to Expect
July 20th, 2025All Eyes on Tesla, ServiceNow, and GE Vernova Ahead of Earnings
July 20th, 2025RTX, Texas Instruments, and Northrop Grumman Earnings in Focus
July 20th, 2025
Member Login